NUT carcinoma (NC) is a rare yet exceptionally aggressive malignancy characterized by a gene fusion involving NUTM1 and a DNA binding fusion partner gene, most frequently BRD4 and BRD3. The resulting fusion protein plays a key role in NC pathogenesis by reshaping the epigenetic landscape and driving the expression of oncogenic transcriptional programs.1 Here, BRD4 is linked to nut midline carcinoma.